# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 608 results.
NeoVax With Nivolumab in Patients With Ovarian Cancer
Status: Not yet recruiting
Last Changed: Mar 05, 2020
First Received: Jul 18, 2019
Disease(s): Ovarian Cancer
Intervention(s): Nivolumab, NeoVax, Core Needle Biopsy
Locations: Dana Farber Cancer Institute, Boston, Massachusetts, United States
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Apr 23, 2019
First Received: Apr 23, 2019
Disease(s): Ovarian Cancer
Intervention(s): Anlotinib
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Status: Recruiting
Last Changed: Jan 27, 2020
First Received: May 22, 2018
Disease(s): Ovarian Cancer
Intervention(s): Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Platino-resistance in Ovarian Cancer
Status: Recruiting
Last Changed: Jan 29, 2020
First Received: May 17, 2019
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Patients treated with platinum based-chemotherapy
Locations: Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 03, 2020
First Received: Jan 03, 2020
Disease(s): Ovarian Cancer
Intervention(s): Niraparib
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Nov 06, 2019
First Received: Aug 21, 2018
Disease(s): Ovarian Cancer
Intervention(s): AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD), Placebo
Locations: Arizona Oncology, Phoenix, Arizona, United States
Kaiser Permanente Oakland, Oakland, California, United States
Stanford University, Palo Alto, California, United States
Kaiser Permanente Roseville, Roseville, California, United States
Kaiser Permanente Sacramento, Sacramento, California, United States
... and 19 other locations.
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Status: Not yet recruiting
Last Changed: Mar 10, 2020
First Received: Jan 23, 2020
Disease(s): Ovarian Cancer
Intervention(s): Olaparib, Ceralasertib, Placebo to match olaparib
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
Status: Recruiting
Last Changed: Feb 20, 2020
First Received: May 03, 2019
Disease(s): Ovarian Cancer
Intervention(s): Palbociclib 125mg, Letrozole 2.5mg
Locations: Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
CPO Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil
Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil
AC Camargo Cancer Center, São Paulo, Brazil
Hospital Beneficência Portuguesa, São Paulo, Brazil
... and 3 other locations.
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status: Recruiting
Last Changed: Mar 18, 2020
First Received: Aug 11, 2017
Disease(s): Ovarian Cancer
Intervention(s): Fostamatinib and Paclitaxel
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
Status: Recruiting
Last Changed: Mar 30, 2020
First Received: Nov 09, 2018
Disease(s): Advanced Ovarian Cancer
Intervention(s): Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
Locations: Research Site, Concord, California, United States
Research Site, Foothill Ranch, California, United States
Research Site, Los Angeles, California, United States
Research Site, Oakland, California, United States
Research Site, Orange, California, United States
... and 220 other locations.